JP2024514087A5 - - Google Patents
Info
- Publication number
- JP2024514087A5 JP2024514087A5 JP2023559990A JP2023559990A JP2024514087A5 JP 2024514087 A5 JP2024514087 A5 JP 2024514087A5 JP 2023559990 A JP2023559990 A JP 2023559990A JP 2023559990 A JP2023559990 A JP 2023559990A JP 2024514087 A5 JP2024514087 A5 JP 2024514087A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical product
- amino acid
- acid sequence
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163167111P | 2021-03-28 | 2021-03-28 | |
| US63/167,111 | 2021-03-28 | ||
| PCT/US2022/022198 WO2022212286A1 (en) | 2021-03-28 | 2022-03-28 | Methods for treating cancer using anti-ctla4 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514087A JP2024514087A (ja) | 2024-03-28 |
| JP2024514087A5 true JP2024514087A5 (https=) | 2025-04-04 |
Family
ID=83456928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559990A Pending JP2024514087A (ja) | 2021-03-28 | 2022-03-28 | 抗ｃｔｌａ４抗体を用いたがんの治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240209091A1 (https=) |
| EP (1) | EP4313147A4 (https=) |
| JP (1) | JP2024514087A (https=) |
| CN (1) | CN117794569A (https=) |
| WO (1) | WO2022212286A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4611905A1 (en) * | 2022-11-05 | 2025-09-10 | Adagene Pte. Ltd. | Methods for treating cancer using anti-ctla4 antibody in combination with pembrolizumab |
| WO2024216179A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Methods for treating cancer using activatable anti-ctla4 antibody in combination with pembrolizumab |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110194B2 (en) * | 2005-12-07 | 2012-02-07 | Medarex, Inc. | CTLA-4 antibody dosage escalation regimens |
| AU2014337063A1 (en) * | 2013-10-18 | 2016-05-19 | Adaptive Biotechnologies Corp. | Predicting patient responsiveness to immune checkpoint inhibitors |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| JPWO2020149026A1 (ja) * | 2019-01-04 | 2021-11-18 | 国立大学法人京都大学 | Ｐｄ−１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| EP4559477A3 (en) * | 2020-05-13 | 2025-08-13 | Adagene AG | Compositions and methods for treating cancer |
-
2022
- 2022-03-28 WO PCT/US2022/022198 patent/WO2022212286A1/en not_active Ceased
- 2022-03-28 EP EP22781974.5A patent/EP4313147A4/en active Pending
- 2022-03-28 CN CN202280037120.1A patent/CN117794569A/zh active Pending
- 2022-03-28 JP JP2023559990A patent/JP2024514087A/ja active Pending
- 2022-03-28 US US18/553,043 patent/US20240209091A1/en active Pending